163 related articles for article (PubMed ID: 29332600)
21. Computational design of Tryprostatin-A derivatives as novel αβ-tubulin inhibitors.
Fani N; Bordbar AK; Ghayeb Y; Sepehri S
J Biomol Struct Dyn; 2015; 33(3):471-86. PubMed ID: 24606044
[TBL] [Abstract][Full Text] [Related]
22. EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.
Zhang F; Zhang H; Wang F
J BUON; 2016; 21(6):1482-1490. PubMed ID: 28039712
[TBL] [Abstract][Full Text] [Related]
23. A drug design strategy based on molecular docking and molecular dynamics simulations applied to development of inhibitor against triple-negative breast cancer by Scutellarein derivatives.
Akash S; Aovi FI; Azad MAK; Kumer A; Chakma U; Islam MR; Mukerjee N; Rahman MM; Bayıl I; Rashid S; Sharma R
PLoS One; 2023; 18(10):e0283271. PubMed ID: 37824496
[TBL] [Abstract][Full Text] [Related]
24. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
[TBL] [Abstract][Full Text] [Related]
25. MeCP2 modulates the canonical Wnt pathway activation by targeting SFRP4 in rheumatoid arthritis fibroblast-like synoviocytes in rats.
Miao CG; Huang C; Huang Y; Yang YY; He X; Zhang L; Lv XW; Jin Y; Li J
Cell Signal; 2013 Mar; 25(3):598-608. PubMed ID: 23200852
[TBL] [Abstract][Full Text] [Related]
26. Secreted frizzled-related protein 4 and its implications in cancer and apoptosis.
Pohl S; Scott R; Arfuso F; Perumal V; Dharmarajan A
Tumour Biol; 2015 Jan; 36(1):143-52. PubMed ID: 25501511
[TBL] [Abstract][Full Text] [Related]
27. Structural and dynamical aspects of Streptococcus gordonii FabH through molecular docking and MD simulations.
Shamim A; Abbasi SW; Azam SS
J Mol Graph Model; 2015 Jul; 60():180-96. PubMed ID: 26059477
[TBL] [Abstract][Full Text] [Related]
28. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Choubey SK; Jeyaraman J
J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
[TBL] [Abstract][Full Text] [Related]
29. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
30. Computational investigation of inhibitory mechanism of flavonoids as bovine serum albumin anti-glycation agents.
Johari A; Moosavi-Movahedi AA; Amanlou M
Daru; 2014 Dec; 22(1):79. PubMed ID: 25498599
[TBL] [Abstract][Full Text] [Related]
31. Molecular docking and dynamic simulation evaluation of Rohinitib - Cantharidin based novel HSF1 inhibitors for cancer therapy.
Agarwal T; Annamalai N; Khursheed A; Maiti TK; Arsad HB; Siddiqui MH
J Mol Graph Model; 2015 Sep; 61():141-9. PubMed ID: 26245696
[TBL] [Abstract][Full Text] [Related]
32. Is the Sudlow site I of human serum albumin more generous to adopt prospective anti-cancer bioorganic compound than that of bovine: A combined spectroscopic and docking simulation approach.
Joshi R; Jadhao M; Kumar H; Ghosh SK
Bioorg Chem; 2017 Dec; 75():332-346. PubMed ID: 29096094
[TBL] [Abstract][Full Text] [Related]
33. Computational Exploration of Anti-Cancer Potential of GUAIANE Dimers from
Shams Ul Hassan S; Abbas SQ; Hassan M; Jin HZ
Anticancer Agents Med Chem; 2022; 22(4):731-746. PubMed ID: 34645380
[TBL] [Abstract][Full Text] [Related]
34. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.
Mirza SB; Salmas RE; Fatmi MQ; Durdagi S
J Mol Graph Model; 2016 May; 66():99-107. PubMed ID: 27054972
[TBL] [Abstract][Full Text] [Related]
35. Design of novel lead molecules against RhoG protein as cancer target - a computational study.
Dasari T; Kondagari B; Dulapalli R; Abdelmonsef AH; Mukkera T; Padmarao LS; Malkhed V; Vuruputuri U
J Biomol Struct Dyn; 2017 Nov; 35(14):3119-3139. PubMed ID: 27691842
[TBL] [Abstract][Full Text] [Related]
36. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.
Li HL; Ma Y; Ma Y; Li Y; Chen XB; Dong WL; Wang RL
Oncotarget; 2017 May; 8(20):33225-33240. PubMed ID: 28402259
[TBL] [Abstract][Full Text] [Related]
37. Computational design of prospective molecular targets for Burkholderia cepacia complex by molecular docking and dynamic simulation studies.
Skariyachan S; Praveen PKU; Uttarkar A; Niranjan V
Proteins; 2023 Jun; 91(6):724-738. PubMed ID: 36601892
[TBL] [Abstract][Full Text] [Related]
38. In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc).
Pagadala NS; Perez-Pineiro R; Wishart DS; Tuszynski JA
Eur J Med Chem; 2015 Feb; 91():118-31. PubMed ID: 25042003
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
Chen DX; Huang J; Liu M; Xu YG; Jiang C
Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
[TBL] [Abstract][Full Text] [Related]
40. Structure versus function-The impact of computational methods on the discovery of specific GPCR-ligands.
Bermudez M; Wolber G
Bioorg Med Chem; 2015 Jul; 23(14):3907-12. PubMed ID: 25828056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
